澳门广东会(中国·VIP认证)股份有限公司
澳门广东会
TaiGen Biotechnology
0
0
0
About
Overview
Steering Committee
Career
Management Team
Milestones
Board of Directors
About Us
TaiGen is a discovery-based and market-focused pharmaceutical company engaging in the development of novel therapeutics for infectious diseases and other indications with high degree of unmet medical needs.
R&D Center
Pipeline
R&D Progress
Antibiotic
Taigexyn®
Influenza Antiviral
TG-1000
HCV Antiviral
Furaprevir
Stem Cell Mobilizer
Burixafor
Research
R&D Center
TaiGen’s dedicated team of professional scientists perform cutting edge research in drug discovery to advance programs efficiently. Our pipeline of anti-infective & anti-inflammatory programs are the fruits of both internal research as well as in-licensed programs.
News
News
Investors
Investors
Financial Information
Material Information
Material Information
Shareholders' Information
Shareholders' Information
Corporate Governance
Investor FAQs
Investors
Communicating with investors, cultivating long-term investor relations and highlighting corporate’s value.
Business & Partnership
ESG
Contact Us
Home
繁中
Pipeline
R&D Progress
Taigexyn®
more
Discovery Research
Preclinical
I
Phase
II
Phase
III
Phase
NDA
Marketed
Community Acquired Pneumonia (Oral)
Taiwan IND
Community Acquired Pneumonia (I.V.)
Taiwan IND
Community Acquired Pneumonia (Oral)
China IND
Community Acquired Pneumonia (I.V.)
China IND
Community Acquired Pneumonia (I.V.)
Russia IND
CAP / Diabetic Foot Infection (Oral)
US IND
Download
TG-1000
more
Discovery Research
Preclinical
I
Phase
II
Phase
III
Phase
NDA
Marketed
Influenza A, B
US / China IND
Download
Furaprevir
more
Discovery Research
Preclinical
I
Phase
II
Phase
III
Phase
NDA
Marketed
HCV (Furaprevir)
US / Taiwan IND
HCV (Furaprevir+Imitasvir)
China IND
Download
Burixafor
more
Discovery Research
Preclinical
I
Phase
II
Phase
III
Phase
NDA
Marketed
Stem Cell transplantation
US IND
Chemosenzitization
China IND
Download
Home
R&D Center
Research
网站首页
澳门广东会